Loading cancer entity…
Loading cancer entity…
Clinical trials
185 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06014905 | Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma | recruiting | Phase 1 | 50 | Charlie Wang, MD, PhDOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07150806 | RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | recruiting | Phase 1 / Phase 2 | 30 | Joshua PalmerOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07652762 |
| IN10018 in Combination With Dalpiciclib for Progressive Meningiomas |
| recruiting |
| Phase 1 |
| 24 |
| Capital Medical UniversityOTHER |
| 1 |
| Aug 7, 2026 |
| clinicaltrials |
| NCT03604978 | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | active not recruiting | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07708285 | Luvometinib in Combination With Serplulimab for NF2-Related Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06668987 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma | completed | Phase 1 / Phase 2 | 10 | Heron Neutron Medical Corp.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07353229 | 68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma | suspended | Phase 1 | 24 | Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04997317 | Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide(PROMENADE) | recruiting | Phase 1 / Phase 2 | 18 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT01117844 | Proton Radiation For Meningiomas and Hemangiopericytomas | completed | Phase 1 / Phase 2 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT03631953 | Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas(ALTREM) | unknown | Phase 1 | 25 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03953131 | Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas | completed | Phase 1 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT03267836 | Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma | terminated | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT01024907 | Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas | completed | Phase 1 / Phase 2 | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT03936426 | Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™ | completed | Phase 1 / Phase 2 | 5 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | Apr 20, 2020 | clinicaltrials |
| NCT01151670 | Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors | completed | Phase 1 | 18 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01144247 | Cellular Immunotherapy Study for Brain Cancer(alloCTL) | completed | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 27, 2016 | clinicaltrials |
| NCT00326664 | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2016 | clinicaltrials |
| NCT01119599 | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00946335 | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2014 | clinicaltrials |
| NCT02084927 | Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery | unknown | Phase 1 | 62 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Mar 12, 2014 | clinicaltrials |
| NCT00052780 | Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors | completed | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00063973 | Cilengitide in Treating Children With Refractory Primary Brain Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00100880 | Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT01076530 | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 2 | May 3, 2013 | clinicaltrials |
| NCT00053963 | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors | terminated | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00363272 | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2026source: clinicaltrials